146 related articles for article (PubMed ID: 37036189)
1. Predictive significance of PRR11 in prognosis and immune infiltration of glioma patients.
Han W; Chen L
Mol Carcinog; 2023 Jul; 62(7):975-990. PubMed ID: 37036189
[TBL] [Abstract][Full Text] [Related]
2. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
3. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma.
Hu A; Tang K; Liu J; Han X; Chen Q
Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443
[TBL] [Abstract][Full Text] [Related]
4. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
[TBL] [Abstract][Full Text] [Related]
5. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
6. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
[TBL] [Abstract][Full Text] [Related]
7. Role of Prognostic Marker
Wang WH; Ma CG; Cui YS; Bai BY; Sheng ZM; Liu J; Li A; Zhang BG
Biomed Environ Sci; 2023 Sep; 36(9):862-868. PubMed ID: 37803898
[TBL] [Abstract][Full Text] [Related]
8. High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.
Wang HY; Xie Y; Du H; Luo B; Li Z
PeerJ; 2023; 11():e16104. PubMed ID: 37810780
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
10. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
11.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PRR11 and immune cell infiltration in Ewing sarcoma.
Wen J; Wan L; Dong X
PLoS One; 2024; 19(3):e0299720. PubMed ID: 38427643
[TBL] [Abstract][Full Text] [Related]
13. miR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway.
Li Y; Ma X; Wang Y; Li G
Biomed Pharmacother; 2017 Sep; 93():435-443. PubMed ID: 28666210
[TBL] [Abstract][Full Text] [Related]
14. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
15. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
16. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma.
Dong T; Zhang B; Zhang R; Wang C; Liu X; Wang F; Hao N; Tan K; Chang YZ
Front Oncol; 2022; 12():963096. PubMed ID: 36237302
[TBL] [Abstract][Full Text] [Related]
17. PRR11 promotes cell proliferation by regulating PTTG1 through interacting with E2F1 transcription factor in pan-cancer.
Zhang H; He Z; Qiu L; Wei J; Gong X; Xian M; Chen Z; Cui Y; Fu S; Zhang Z; Hu B; Zhang X; Lin S; Du H
Front Mol Biosci; 2022; 9():877320. PubMed ID: 36060253
[TBL] [Abstract][Full Text] [Related]
18. LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma.
Zhu X; Chen D; Sun Y; Yang S; Wang W; Liu B; Gao P; Li X; Wu L; Ma S; Lin W; Ma J; Yan D
BMC Cancer; 2023 Feb; 23(1):120. PubMed ID: 36747161
[TBL] [Abstract][Full Text] [Related]
19. RGS16 promotes glioma progression and serves as a prognostic factor.
Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
[TBL] [Abstract][Full Text] [Related]
20. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
